1h Free Analyst Time
Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) ImpactSpeak directly to the analyst to clarify any post sales queries you may have.
Summary
This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing.
Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe.
Scope
- Report provides in-house analyst expertise on the results of a 5 minute survey of 75 the publisher's Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020.
Reasons to Buy
Objectives included -
- Benchmark companies’ primary concerns
- Determine the impact of COVID-19 to date on supply chains
- Assess companies’ strategic future plans
- Track changes to corporate strategy and attitudes
Table of Contents
- Executive Summary
- Study Design
- Background, Objectives, and Design
- Respondent Mix
- Primary Business Concerns
- Impact of COVID-19 on Company Revenue
- Dedicated Planning Team
- Supply Chain Concerns
- Clinical Trial Materials
- Marketed Drugs
- Spotlight on US Manufacturing
- Import/Export Risks
- Clinical Trial Concerns
- Addressing Clinical Trial Disruptions
- Planning Scenarios
- In Their Own Words
- Suppliers
- Manufacturing Sites
- Small Molecule API
- Summary
- Appendix
